Articles
Charise Gleason, MSN, NP-C, AOCNP, and Nikki Barkett, RN, BSN, OCN, break down the misconceptions that patients with multiple myeloma may have about the different treatment regimens and how those misconceptions can affect their views on treatment adherence. Read More ›
Charise Gleason, MSN, NP-C, AOCNP, and Nikki Barkett, RN, BSN, OCN, discuss the multiple potential barriers to treatment adherence that some patients with multiple myeloma may face in their cancer journey and how they utilize some of their best practices to keep patients on therapy. Read More ›
Clinicians spend a lot of time focusing on treatment plans for patients with multiple myeloma. However, quality-of-life issues are just as important to patients. Please join Charise Gleason, MSN, NP-C, AOCNP, and Nikki Barkett, RN, BSN, OCN, as they share their approach to helping patients cope and maintain an acceptable quality of life. Read More ›
Charise Gleason, MSN, NP-C, AOCNP, and Nikki Barkett, RN, BSN, OCN, discuss the multiple potential barriers to treatment adherence that some patients with multiple myeloma may face in their cancer journey. Read More ›
Relapsing during therapy is devastating for patients with cancer. Charise Gleason, MSN, NP-C, AOCNP, and Nikki Barkett, RN, BSN, OCN, share their best practices for how to interact with patients who will have many questions about what it means for them and what therapy options are next. Read More ›
Setting expectations for patients with cancer can help them prepare for the high and low points in their treatment journey. Join Charise Gleason, MSN, NP-C, AOCNP, and Nikki Barkett, RN, BSN, OCN, as they talk about the importance of setting expectations early for patients with multiple myeloma. Read More ›
Charise Gleason, MSN, NP-C, AOCNP, and Nikki Barkett, RN, BSN, OCN, discuss how they use a team approach to help patients remain on their multiple myeloma therapy and remain on therapy longer. Read More ›
By William King
Currently, 33 biosimilar products have been approved by the FDA, 22 of which have been launched in the United States. Read More ›
Final results from the pivotal phase 3 KEYNOTE-355 trial showed that the addition of pembrolizumab (Keytruda) to chemotherapy resulted in a statistically significant and clinically meaningful improvement in overall survival (OS) compared with chemotherapy alone in patients with metastatic triple-negative breast cancer (TNBC) whose tumors expressed PD-L1 with a combined positive score (CPS) ≥10. Read More ›
The antibody–drug conjugate polatuzumab vedotin-piiq (Polivy) added to R-CHP (rituximab [Rituxan], cyclophosphamide, doxorubicin, and prednisone) achieved a 27% reduction in the risk for progression or death compared with the standard regimen of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) as first-line therapy for patients with intermediate- and high-risk diffuse large B-cell lymphoma (DLBCL). Read More ›